enGene Presents 56% Complete Response Rate for Detalimogene in Bladder Cancer Study

PUBT · 2d ago
enGene Presents 56% Complete Response Rate for Detalimogene in Bladder Cancer Study
  • enGene Therapeutics plans to initiate detalimogene’s biologics license application in fourth-quarter 2026, targeting potential approval in 2027.
  • Detalimogene achieved a 56% complete response rate in 120 evaluable patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
  • Median response duration reached 10.1 months; an estimated 43% of responders maintained responses for at least 12 months.
  • Six-month data from the detalimogene-surfactant cohort are expected in mid-2027.
  • Cash totaled $245.8 million as of October 31, 2026, supporting operating flexibility through potential filing and approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.